H.C. Wainwright raised the firm’s price target on Maze Therapeutics (MAZE) to $110 from $60 and keeps a Buy rating on the shares. The firm believes Maze’s Phase 2 HORIZON data for MZE829 demonstrated “unambiguously positive” efficacy in APOL1-mediated kidney disease. MZE829 has established a “best-in-class profile and a de-risked regulatory path,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
- Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
- Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
- Maze Therapeutics adds Neil Kumar to board leadership
- Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls